Can You Take Farxiga (Dapagliflozin) with Tadalafil?

Pharmacokinetic Profile: Why These Two Drugs Don't Compete

Dapagliflozin is eliminated primarily through UGT1A9-mediated glucuronidation in the liver and kidney, with less than 10% of its clearance attributable to CYP-mediated oxidation [1]. Tadalafil, by contrast, is a CYP3A4 substrate with no meaningful UGT contribution [2]. Because they travel through entirely separate metabolic pathways, neither drug raises or lowers plasma concentrations of the other.

The FDA-approved prescribing information for dapagliflozin lists formal drug-drug interaction studies with pioglitazone, metformin, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, and valsartan. None produced clinically significant pharmacokinetic changes [1]. No formal study with tadalafil exists, but the absence of CYP3A4 involvement in dapagliflozin clearance makes a kinetic interaction implausible based on first principles.

Tadalafil's label similarly shows no interaction signal with drugs cleared by glucuronidation [2]. P-glycoprotein transport plays a minor role in tadalafil disposition, and dapagliflozin is not a P-gp inhibitor or inducer. The net result: co-administration does not require timing separation or dose modification on pharmacokinetic grounds alone.

Blood Pressure: The Additive Pharmacodynamic Effect

Both drugs independently lower blood pressure. This overlap is the only interaction of clinical relevance.

Dapagliflozin reduces systolic blood pressure by approximately 3 to 5 mmHg through osmotic diuresis and mild natriuresis, a finding consistent across the DAPA-HF (N=4,744) and DECLARE-TIMI 58 (N=17,160) trials [3][4]. Tadalafil produces vasodilation via nitric oxide/cGMP pathway potentiation. In the AMBITION and tadalafil BPH trials, mean systolic BP reduction was 1.6 to 4.2 mmHg depending on dose [2][5].

When combined, the theoretical additive drop ranges from 5 to 9 mmHg systolic. For a patient with a resting systolic pressure of 125 mmHg, this brings them to approximately 116 to 120 mmHg. That is well-tolerated. For a patient already at 95 mmHg systolic (common in advanced heart failure), the combined effect could produce symptomatic orthostatic hypotension.

A practical risk-stratification approach: patients with baseline systolic BP above 110 mmHg and no active diuretic dose escalation can generally start both drugs without special precaution. Patients below 100 mmHg systolic, those on loop diuretics, or those with autonomic neuropathy warrant closer monitoring (orthostatic vitals at days 3, 7, and 14).

Volume Depletion: The SGLT2 Factor

SGLT2 inhibitors increase urinary glucose excretion by 60 to 80 grams per day, carrying approximately 300 to 500 mL of additional water with it [6]. This osmotic diuresis is the mechanism behind the BP reduction. It also creates a clinical state where patients are more susceptible to hypotension from any additional vasodilatory or volume-depleting agent.

The FDA label for dapagliflozin includes a warning about volume depletion in patients on loop diuretics, those with eGFR below 60 mL/min/1.73m², and adults over age 65 [1]. Tadalafil's vasodilatory properties do not directly cause volume loss, but they reduce vascular resistance, which magnifies the hemodynamic impact of any concurrent volume deficit.

Practical counseling for patients on both medications: maintain fluid intake of at least 2 liters daily (absent fluid restriction for heart failure), rise slowly from seated or lying positions, and report lightheadedness or near-syncope promptly. These instructions matter most during the first two weeks of combination therapy and during illness with vomiting or diarrhea.

DAPA-HF and Heart Failure Patients on PDE5 Inhibitors

The DAPA-HF trial enrolled patients with heart failure with reduced ejection fraction (HFrEF), NYHA class II-IV, with ejection fractions of 40% or below [3]. Approximately 3% of enrolled men were taking PDE5 inhibitors at baseline. The trial did not exclude them. No differential safety signal for hypotension or syncope was reported in this subgroup in the published safety analyses.

"The blood pressure lowering with dapagliflozin was modest, and the benefits in heart failure were not driven by hemodynamic unloading alone," noted Dr. John McMurray, DAPA-HF principal investigator, in the 2019 NEJM publication [3]. This is consistent with the idea that dapagliflozin's mechanism in heart failure extends beyond simple diuresis to include metabolic and anti-fibrotic effects.

For the clinician managing a heart failure patient on tadalafil (whether for erectile dysfunction or pulmonary hypertension), the DAPA-HF data provides reassurance that dapagliflozin can be layered in. The reverse scenario (adding tadalafil to a stable dapagliflozin regimen) lacks direct trial data but follows the same pharmacologic logic.

Tadalafil for BPH in Patients Taking Dapagliflozin

Tadalafil 5 mg daily (Cialis for daily use) is FDA-approved for benign prostatic hyperplasia (BPH) symptoms [2]. Many men prescribed this dose also have type 2 diabetes, the primary indication for dapagliflozin. The overlap population is substantial: BPH prevalence exceeds 50% in men over 60, and type 2 diabetes prevalence in this age group is approximately 25% [7].

The BPH dose of tadalafil (5 mg) produces less vasodilation than the on-demand erectile dysfunction dose (10 to 20 mg). Mean systolic BP reduction at the 5 mg dose is 1.6 mmHg versus 3 to 4 mmHg at 20 mg [2]. The combination of dapagliflozin 10 mg plus tadalafil 5 mg daily therefore carries a lower hypotension risk than dapagliflozin plus on-demand 20 mg tadalafil.

No dose reduction of either drug is necessary. Patients should be advised that alcohol (which is independently vasodilatory) adds a third layer of BP reduction and should be limited during the initial combination period.

Renal Considerations: Shared Organ, Different Mechanisms

Both drugs affect renal hemodynamics, but through unrelated pathways. Dapagliflozin activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular pressure. This is the mechanism behind the renoprotective findings in DAPA-CKD (N=4,304), where dapagliflozin reduced the composite renal endpoint by 39% versus placebo in patients with CKD stages 2-4 [8].

Tadalafil increases renal blood flow modestly through cGMP-mediated vasodilation of renal vasculature. Animal data suggest PDE5 inhibition may be renoprotective in diabetic nephropathy, though human trial data is limited to small studies [9].

The two mechanisms are complementary rather than antagonistic. There is no pharmacologic basis for concern about additive renal injury. Patients with eGFR below 30 mL/min/1.73m² may have altered tadalafil exposure (AUC increased by approximately 50% per the label), and dapagliflozin's glycosuric efficacy diminishes below eGFR 45, though its cardio-renal benefits persist [1][2][8].

Hypoglycemia Risk Assessment

Neither dapagliflozin nor tadalafil causes hypoglycemia as monotherapy. Dapagliflozin's mechanism (blocking glucose reabsorption in the proximal tubule) is insulin-independent and self-limiting: once plasma glucose falls below the SGLT2 transport threshold, glycosuria stops [1].

Tadalafil has no direct effect on glucose metabolism. A small crossover study (N=20) found that tadalafil 10 mg did not alter insulin sensitivity, fasting glucose, or postprandial glucose in men with type 2 diabetes [10].

The combination does not increase hypoglycemia risk. If the patient is also taking insulin or a sulfonylurea, the hypoglycemia risk comes from those agents, not from the dapagliflozin-tadalafil pair. This distinction matters for patient counseling: patients sometimes attribute any adverse effect to the newest drug added, so clarifying that these two medications do not interact glycemically helps avoid unnecessary discontinuation.

Genital Infections: A Monitoring Note

SGLT2 inhibitors increase the incidence of genital mycotic infections (vulvovaginal candidiasis in women, balanitis in men) by approximately 4 to 8 percentage points versus placebo [1][4]. Tadalafil does not independently increase infection risk, but increased sexual activity in men using tadalafil for ED could theoretically raise exposure frequency.

The prescribing information for dapagliflozin recommends counseling patients about genital hygiene and early symptom recognition [1]. For men using both dapagliflozin and tadalafil, this counseling is worth reinforcing. Topical antifungals resolve most cases without needing to stop either medication.

When to Reassess the Combination

The combination warrants clinical reassessment in three scenarios. First: acute illness with dehydration (gastroenteritis, post-surgical NPO status). Dapagliflozin should be held during sick days per standard SGLT2 inhibitor guidance, which eliminates any additive hypotension concern temporarily [1]. Second: initiation of a new antihypertensive or diuretic dose increase. The additional BP-lowering from a new agent on top of an existing dapagliflozin-tadalafil regimen may push some patients into symptomatic hypotension. Third: development of autonomic neuropathy, which impairs baroreceptor-mediated compensation.

According to the 2022 ADA Standards of Medical Care, "SGLT2 inhibitors should be continued in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, regardless of HbA1c, given their proven cardiovascular and renal benefits" [11]. Tadalafil should not be a reason to withhold dapagliflozin, and vice versa.

Prescriber Action Summary

No pharmacokinetic interaction exists. The pharmacodynamic interaction (additive BP lowering) is mild in most patients and manageable with standard monitoring. Prescribers should document baseline orthostatic vitals, counsel on hydration, and schedule a follow-up BP check at 1 to 2 weeks. Patients on nitrates remain absolutely contraindicated for tadalafil regardless of dapagliflozin status [2]. The combination of dapagliflozin and tadalafil carries a DDI severity rating of "minor" in most databases and does not appear on any major formulary's hard-stop interaction list.